David B.Katague, B.S., M.S., M.A, Ph.D. Sunset Photo from the Balcony of the Chateau Du Mer Beach House, Boac,Marinduque,Philippines
Welcome to My Site
If this is your first visit, welcome! This site is devoted to my life experiences as a Filipino-American who immigrated from the Philippines to the United States in 1960. I came to the US as a graduate student when I was 26 years old. I am now in my mid-80's and thanks God for his blessings, I have four successful and professional children and six grandchildren here in the US. My wife and I had been enjoying the snow bird lifestyle between US and Philippines after my retirement from USFDA in 2002. Macrine(RIP),Me and my oldest son are the Intellectual migrants. Were were born in the Philippines, came to the US in 1960 and later became US citizens in 1972. Some of the photos and videos in this site, I do not own. However, I have no intention on infringing on your copyrights. Cheers!
Wednesday, June 29, 2011
New Drugs Approved by FDA in 2011
As an FDA Retiree(previously involved with approval of new drugs), I am still interested on new drugs approved recently by FDA. Here is list from Center Watch. Note that there are no new anti-infected drugs in the list. Visit, www.fda.gov for the latest news on drug development and research.
Cardiology/Vascular DiseasesEdarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011
Dermatology/Plastic SurgeryGralise (gabapentin); Abbott; For the treatment of postherpetic neuralgia, Approved February 2011
Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011
Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011
Endocrinology
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011
Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011
Tradjenta (linagliptin); Boehringer Ingelheim; For the treatment of type II diabetes, Approved May 2011
Gastroenterology
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011
Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011
Incivek (telaprevir); Vertex; For the treatment of genotype 1 chronic hepatitis C, Approved May 2011
Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011
Victrelis (boceprevir); Merck; For the treatment of chronic hepatitis C genotype 1, Approved May 2011
Immunology/Infectious Diseases
Benlysta (belimumab); Human Genome Sciences; For the treatment of systemic lupus erythematosus, Approved March 2011
Daliresp (roflumilast); Forest Pharmaceuticals; For the treatment of chronic obstructive pulmonary disease, Approved February 2011
Edurant (rilpivirine); Tibotec; For the treatment of HIV-1, Approved May 2011
Gralise (gabapentin); Abbott; For the treatment of postherpetic neuralgia, Approved February 2011
Incivek (telaprevir); Vertex; For the treatment of genotype 1 chronic hepatitis C, Approved May 2011
Victrelis (boceprevir); Merck; For the treatment of chronic hepatitis C genotype 1, Approved May 2011
Musculoskeletal
Actemra (tocilizumab); Genentech; For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011
Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011
Neurology
Abstral (fentanyl sublingual tablets); ProStrakan; For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011
Gralise (gabapentin); Abbott; For the treatment of postherpetic neuralgia, Approved February 2011
Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of restless legs syndrome, Approved April 2011
Viibryd (vilazodone hydrochloride); Clinical Data; For the treatment of major depressive disorder, Approved January 2011
Obstetrics/Gynecology
Makena (hydroxyprogesterone caproate injection); Hologic; For the prevention of risk of preterm birth, Approved February 2011
Oncology
Abstral (fentanyl sublingual tablets); ProStrakan; For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011
Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011
Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011
Vandetanib (vandetanib); Astra Zeneca; For the treatment of thyroid cancer, Approved April 2011
Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011
Zytiga (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011
OtolaryngologyVandetanib (vandetanib); Astra Zeneca; For the treatment of thyroid cancer, Approved April 2011
Pediatrics/Neonatology
Actemra (tocilizumab); Genentech; For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011
Daliresp (roflumilast); Forest Pharmaceuticals; For the treatment of chronic obstructive pulmonary disease, Approved February 2011
Psychiatry/Psychology
Viibryd (vilazodone hydrochloride); Clinical Data; For the treatment of major depressive disorder, Approved January 2011
Pulmonary/Respiratory Diseases
Daliresp (roflumilast); Forest Pharmaceuticals; For the treatment of chronic obstructive pulmonary disease, Approved February 2011
Rheumatology
Actemra (tocilizumab); Genentech; For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011
Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011
Source: Center Watch
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment